Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection

1 Dec 2005

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 16341237
DOI: 10.1038/ncponc0355

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selectionPMID 16341237Read ↗

Role of DNA Methylation in the Pathogenesis and Treatment of Myelodysplastic SyndromesSemantic proximity Read ↗

Current status of epigenetic treatment in myelodysplastic syndromesSemantic proximity Read ↗

Optimizing hypomethylating agents in myelodysplastic syndromesSemantic proximity Read ↗

DNA methyltransferase inhibitors in myelodysplastic syndromeSemantic proximity Read ↗

Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agentsSemantic proximity Read ↗

The biology and treatment of myelodysplastic syndromes.Semantic proximity Read ↗

Established and emerging targeted therapies in the myelodysplastic syndromes.Semantic proximity Read ↗

Current therapeutic approaches for patients with myelodysplastic syndromes.Semantic proximity Read ↗

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read ↗

DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic SyndromesSemantic proximity Read ↗

[Management of myelodysplastic syndromes].Semantic proximity Read ↗

Inhibitors of DNA methylation in the treatment of hematological malignancies and MDSSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.